---
phase: "2"
manager: head-of-research
ics_spawned:
  - market-research-analyst
  - competitive-intelligence-analyst
status: ready_for_csuite
recommendation: approve
llm_tier: strong-general
llm_model: composer-2.5
generation_profile: none
generation_used: none
fallback_applied: false
runId: 1784309147792-head-of-research
---

# Manager brief — Phase 2 Market — head-of-research

## Summary (5 bullets max)

- **Blocker resolved:** IC handoffs were complete but Phase 2 lacked `02-evidence-base.md` and this manager brief — both now written; evidence merged from market + competitive IC artifacts.
- **Evidence verdict:** Problem framing holds — sorbent/passive AWG addresses a real RH-floor gap vs refrigeration incumbents; **portable zero-power cartridge** white-space confirmed with no direct incumbent SKU.
- **Market sizing:** TAM/SAM/SOM triangulated with **Low confidence** on dollar SAM; bootstrapped SOM USD 0.1M–0.8M (50–400 units) is plausible for Ontario beachhead.
- **Assumptions:** A4 (MOF unavailable) **confirmed**; A5 (WTP premium) **partial** for resilience segment only; A1 (zeolite yield) **still unvalidated** — Phase 9B critical path.
- **Phase status:** Artifacts ready for C-suite review — **do not mark Phase 2 ✅** until verdict + yield/regulatory follow-ups scheduled.

## IC handoffs merged

| IC | Handoff path | Status | llm_tier | generation_used |
|----|--------------|--------|----------|-----------------|
| `market-research-analyst` | `HANDOFFS/2-market-research-analyst.md` | done — ready_to_merge | strong-general | none |
| `competitive-intelligence-analyst` | `HANDOFFS/2-competitive-intelligence-analyst.md` | done — ready_to_merge | strong-general | none |

**Spawn note:** Both ICs completed in prior run (2026-07-17 ~17:20 UTC). This manager run **did not re-spawn** ICs — merged existing handoffs per HEARTBEAT step 4.

## Model routing check

- [x] Every IC packet had `llm_tier` (strong-general)
- [x] Creative ICs used correct `generation_profile` — N/A (none required)
- [x] Fallbacks recorded when Max Mode / plan blocked preferred model — none applied

## Conflicts resolved

- **Product path:** Intake company goal mentions Pi edge control; user resolved **grid-down passive** as primary (`00-intake.md`, `00-passive-grid-down-spec.md`). All Phase 2 artifacts now align — passive primary, powered Pi secondary/legacy.
- **Peer cross-asks:** Market IC requested competitive deep dive; competitive IC requested market WTP validation — both delivered in respective artifacts; no merge conflict.
- **Otherwise:** none

## Artifacts for C-suite review

| Path | Scorecard check |
|------|-----------------|
| `docs/projects/passive-grid/business-idea/02-evidence-base.md` | Deep-research quick brief + gap review; assumption matrix; IC merge |
| `docs/projects/passive-grid/business-idea/02-market-research.md` | TAM/SAM/SOM, 3 avatars, PESTLE, Porter's, 25 sources |
| `docs/projects/passive-grid/business-idea/02-competitive-landscape.md` | 10 competitor profiles, positioning matrix, threat assessment |
| `docs/projects/passive-grid/business-idea/SOURCES/INDEX.md` | 25 indexed sources (src-001–src-025) |
| `docs/projects/passive-grid/business-idea/REVIEW/inbox/2-head-of-research-2026-07-17T1725-deliverable.md` | Operator review packet |

## Escalation tags

- **evidence** — SAM confidence Low; no primary interviews; A1 yield unproven
- **scope** — Regulatory path (Health Canada / NSF) not scoped — defer to Phase 8 legal with Phase 3 flag

## Asks for C-suite

1. **Approve** Phase 2 artifact set for Phase 3 strategy kickoff, preserving Low-confidence flags on sizing.
2. **Confirm** grid-down passive remains primary product path (Pi edge control demoted to legacy/optional in messaging).
3. **Schedule** Phase 9B yield proof as gate before any L/day marketing claims in Phase 6+.
4. **Operator:** Clarify Danny's role when convenient — listed as open but non-blocking.

## Recommendation

**approve** — ship Phase 2 artifacts to Phase 3 with documented evidence gaps and confidence labels intact. Do **not** mark runbook Phase 2 ✅ until this brief receives C-suite verdict in `HANDOFFS/2-csuite-review.md`.
